Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. (1998)

Peer-Reviewed Study · Nseyo UO; Shumaker B; Klein EA; Sutherland K · July 1998

Nseyo UO et al., 1998-07: Thirty-six patient clinical series of whole-bladder PDT with porfimer sodium (2 mg/kg IV, 630 nm light at 15 J/cm2) in BCG-refractory carcinoma in situ: 58% complete response at 3 months, 31% durable at a mean 12 months – the real clinical bladder PDT record, using a porphyrin, not methylene blue.

In all patients at least 1 course of bacillus Calmette-Guerin (BCG) had failed. Each patient received a single whole bladder photodynamic therapy treatment, consisting of 2 mg./kg. porfimer sodium intravenously followed 40 to 50 hours later by intravesical red light (630 nm.) at 15 J./cm.2.

Nseyo UO et al., 1998-07: Thirty-six patient clinical series of whole-bladder PDT with porfimer sodium (2 mg/kg IV, 630 nm light at 15 J/cm2) in BCG-refractory carcinoma in situ: 58% complete response at 3 months, 31% durable at a mean 12 months – the real clinical bladder PDT record, using a porphyrin, not methylene blue. C8 Nseyo 1998 (Bladder Photofrin Study Group). Study type: prospective multicentre clinical series, N=36. Country: USA (multi-site). Agent: porfimer sodium 2 mg/kg IV, 40-50 h before intravesical 630 nm light at 15 J/cm2. Funder/conflicts: not in the record. Comparator: none – single-arm; historical alternative was cystectomy. Bearing CONTRADICTS the attribution to methylene blue; the record it does establish is a real, modest clinical PDT result with a different drug. Study type: uncontrolled series.